BBH is heavily allocated to the largest biotech stocks, including a few that hedge funds love to short. Starting with Gilead Sciences (NasdaqGS: GILD), a biotech hedge fund favorite from the long side, that stock is BBH’s largest holding at 15% of the ETF’s weight. [A Different Type of Biotech ETF]

Amgen (NasdaqGS: AMGN), Regeneron Pharmaceuticals (NasdaqGS: REGN) and Celgene (NasdqGS: CELG) are some of hedge funds’ favorite biotechs to short, according to 24/7 Wall Street. None of those three stocks have traded lower this year, though Amgen and Celgene are up “just” 3.8% apiece. Regeneron has surged more than 25%.

In order, Amgen, Celgene and Regeneron combine for combine for about 28% of BBH’s weight. Pharmacyclics is BBH’s smallest holding at a weight of 0.34%.

Market Vectors Biotech ETF

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.